Review
Glycogen synthase kinase 3 as an anticancer drug target: novel experimental findings and trends in the design of inhibitors
Affiliations
- PMID: 23016861
Item in Clipboard
Review
Glycogen synthase kinase 3 as an anticancer drug target: novel experimental findings and trends in the design of inhibitors
Curr Pharm Des.
2013.
Abstract
Glycogen synthase kinase 3 (GSK-3) is a ubiquitous serine/threonine protein kinase participating in numerous pathways. Very important among them are cancer-related pathways, such as Wnt pathway and nuclear factor κB pathway. The recent findings concerning possible applicability of GSK-3 inhibitors as anticancer agents are summarized in this review, and controversies in the data are highlighted. The most actual concepts of GSK-3 inhibitor design are also thoroughly discussed.
Similar articles
-
Glycogen synthase kinase 3 in Wnt signaling pathway and cancer.IUBMB Life. 2015 Dec;67(12):914-22. doi: 10.1002/iub.1454. Epub 2015 Nov 24. IUBMB Life. 2015. PMID: 26600003 Review.
-
Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions.Eur J Med Chem. 2018 Jan 20;144:843-858. doi: 10.1016/j.ejmech.2017.11.103. Epub 2017 Dec 9. Eur J Med Chem. 2018. PMID: 29306837 Review.
-
Glycogen synthase kinase-3 beta inhibitor suppresses Porphyromonas gingivalis lipopolysaccharide-induced CD40 expression by inhibiting nuclear factor-kappa B activation in mouse osteoblasts.Mol Immunol. 2012 Aug;52(1):38-49. doi: 10.1016/j.molimm.2012.04.005. Epub 2012 May 14. Mol Immunol. 2012. PMID: 22580404
-
Glycogen synthase kinase-3β is a crucial mediator of signal-induced RelB degradation.Oncogene. 2011 May 26;30(21):2485-92. doi: 10.1038/onc.2010.580. Epub 2011 Jan 10. Oncogene. 2011. PMID: 21217772
-
Activation of β-catenin by inhibitors of glycogen synthase kinase-3 ameliorates cisplatin-induced cytotoxicity and pro-inflammatory cytokine expression in HEI-OC1 cells.Toxicology. 2014 Jun 5;320:74-82. doi: 10.1016/j.tox.2014.01.013. Epub 2014 Feb 19. Toxicology. 2014. PMID: 24560772
Cited by
-
Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia.Sci Rep. 2019 Jan 24;9(1):606. doi: 10.1038/s41598-018-37174-6. Sci Rep. 2019. PMID: 30679640 Free PMC article.
-
Integrating Machine Learning-Based Virtual Screening With Multiple Protein Structures and Bio-Assay Evaluation for Discovery of Novel GSK3β Inhibitors.Front Pharmacol. 2020 Sep 11;11:566058. doi: 10.3389/fphar.2020.566058. eCollection 2020. Front Pharmacol. 2020. PMID: 33041806 Free PMC article.
-
[Screening and identification of novel drug-resistant genes in CD133+ and CD133- lung adenosarcoma cells using cDNA microarray].Zhongguo Fei Ai Za Zhi. 2014 Jun 20;17(6):437-43. doi: 10.3779/j.issn.1009-3419.2014.06.01. Zhongguo Fei Ai Za Zhi. 2014. PMID: 24949682 Free PMC article. Chinese.
-
Microsecond molecular dynamics simulations and dynamic network analysis provide understanding of the allosteric inactivation of GSK3β induced by the L343R mutation.J Mol Model. 2019 Apr 4;25(5):111. doi: 10.1007/s00894-019-4003-x. J Mol Model. 2019. PMID: 30949773
-
Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.Sci Transl Med. 2018 Mar 7;10(431):eaam8460. doi: 10.1126/scitranslmed.aam8460. Sci Transl Med. 2018. PMID: 29515000 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
